Wednesday, March 9, 2016

News: EOS imaging and Stryker announce a Co-promotion Agreement for the UK market

Partnership will grant UK hospitals access to global solutions for orthopaedic care

PARIS--()--EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, announced today a co-promotion agreement with Stryker’s European Spine business for the UK market as part of its ongoing development strategy. Under the terms of this exclusive agreement, Stryker’s UK sales force will promote EOS imaging’s platform products to existing and prospective customers of Stryker.
“We are excited to partner with EOS imaging to provide streamlined and integrated surgical solutions to our customers and provide access in the UK to the safest and most innovative way to assess and treat spinal pathologies.”
Tweet this
This exclusive partnership gives us a stronger access to the orthopaedic customer’s base in one of the most important markets in Europe. Stryker’s Spine sales force will strongly reinforce our go-to market capacity in the UK and we’re very pleased to partner with one of the fastest growing companies within the spine implant business in the UK. Combining our respective products range and resources into one of the best offerings is undoubtedly a great advantage for our companies and our mutual customers," said Marie Meynadier, CEO of EOS imaging.
With the combination of EOS low-dose 2D/3D imaging and 3D planning solutions, and Stryker’s Spine portfolio, surgeons will have the ability to visualize the patient’s spine and lower limbs in 2D and 3D, have access to valuable and highly accurate anatomical information, define adequate treatment strategies and follow post-operative conditions.
Guillaume Joseph, VP & GM of Stryker’s European Spine division, added, “We are excited to partner with EOS imaging to provide streamlined and integrated surgical solutions to our customers and provide access in the UK to the safest and most innovative way to assess and treat spinal pathologies.”
For more information about EOS imaging and Stryker, please visit www.eos-imaging.com and www.stryker.com
EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.
EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

Next press release: 2015 Full-year results and 2016 First-quarter sales on April 28, 2016
About EOS imaging
EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system dedicated to osteoarticular pathologies and orthopaedics, as well as associated solutions. The Company is authorized to market in 48 countries, including the United States (FDA), Japan and the European Union (EC). The Group posted 2014 revenues of €20.1 million and employs 107 people including an R&D team of 39 engineers. The Group is based in Paris and has five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.
About Stryker
Stryker is one of the world's leading medical technology companies and, together with our customers, we are driven to make healthcare better. The Company offers a diverse array of innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. Stryker is active in over 100 countries around the world.

Contacts

Media Contacts
The Ruth Group (US)
Press relations / Joanna Zimmerman
Ph: 646-536-7006
or
Oli Prosperi
General Manager, Spine and Orthobiologics
Stryker UK
Ph: +44 1635 262400
or
Financial Contacts
Anne Renevot
CFO
Ph: +33 (0)1 55 25 61 24
or
NewCap
Financial communication and investor relations
Pierre Laurent
Ph: +33 (0)1 44 71 94 91

Published at BusinessWire

No comments:

Post a Comment